- Single-molecule real-time (SMRT) sequencing, a cutting-edge long-read sequencing technology, is becoming increasingly vital in genomics research, clinical diagnostics, and precision medicine due to its ability to provide high-throughput, highly accurate sequencing with epigenetic insight, real-time analysis, and minimal amplification bias
- The surging demand for advanced genomic technologies, increasing prevalence of genetic disorders and cancers, and expanding applications in transcriptomics and epigenetics are among the primary factors driving the adoption of SMRT sequencing across academic, clinical, and biopharmaceutical sectors
- North America dominated the single-molecule real-time sequencing (SMRT) market, with the largest revenue share of 50.70% in 2024, driven by strong R&D infrastructure, high healthcare spending, and the presence of leading biotechnology companies. The U.S. leads the regional growth due to continuous innovation, robust funding for genomics research, and early clinical integration of SMRT technologies
- Asia-Pacific is projected to witness the fastest growth in the single-molecule real-time sequencing (SMRT) market during the forecast period, with a CAGR of 14.8%, propelled by rising investment in genomics, government-backed precision medicine initiatives, and increasing access to advanced sequencing technologies in countries such as China, Japan, and India
- DNA sequencing segment dominated the single-molecule real-time sequencing (SMRT) market by application with a market share of 38.7% in 2024, driven by its critical role in clinical diagnostics, precision medicine, and large-scale genomic projects that require accurate and comprehensive genetic analysis
